3m Innovative Properties Company

Minnesota Mining and Manufacturing Company

Daniel C Duan

James S Stefely

David W Schultz

Robert A Asmus

Olester Benson, Jr

Timothy M Dietz

Rosa Uy

Craig Allen Perman

Mark Steven Schaberg

Luke E Schallinger

Moses Mekala David

Kurt J Halverson

Michael R Berrigan

Robert A Scherrer

Kenneth Brian Wood

Nathan E Schultz

Fuming B Li

Chester L Leach

Terence M Fogarty

Seth M Kirk

Stephen W Stein

Cheryl L Moore

John M Sebastian

Sanjay L Patil

Pierre H LePere

Bryan L Gerhardt

Stanley Rendon

James T Wolter

Peter R Johnson

James E Garbe

Michael W Mueting

Jamieson C Keister

Himanshu Jasuja

Armin J Paff

Hye-Ok Choi

Chan U Ko

Kaveh Pournoor

Donald W Edwards

William L Howard, Jr

Zackary J Becker

Marla R Emery

Jennifer E Raeder-Devens

A pleated multilayer air filter assembly including a primary filtration layer and a prefilter layer that are bonded to each other and are co-pleated with each other. The primary filtration layer includes meltblown electret fibers. The prefilter layer includes meltspun, spunbonded electret fibers that comprise a radially outer surface comprising polymethylpentene. The ratio of Effective Fiber Diameter of the fibers of the primary filtration layer to Effective Fiber Diameter of the fibers of the primary filtration layer is at least 1.5.

Pleated filtration assembly comprising spunbonded prefilter

A method of making active pharmaceutical ingredient particles with surface-modified nanoparticles deposited on the particles' surfaces, the method comprising: providing a plurality of media particles having surfaces with the surface-modified nanoparticles deposited on the surfaces; mixing the plurality of media particles with the active ingredient particles, both of which are in dry form, to provide active ingredient particles having surfaces with the surface-modified nanoparticles deposited on the surfaces; and separating the plurality of media particles from the active ingredient particles having surfaces with the surface-modified nanoparticles deposited on the surfaces is disclosed.

Method of making a dry powder pharmaceutical composition

A method of treating a patient with a microneedle array having an active agent disposed on at least a portion of one or more of the microneedles, wherein the array with active agent is characterized by a first optical response when probed with a selected incident light spectrum. The array with active agent is applied to a skin surface, optionally allowed to remain on the skin surface for a specified time, and removed. The used array is probed with the selected incident light spectrum, a second optical response is sensed, and the difference between the first optical response and the second optical response is determined and compared to a predetermined threshold value.

Microneedle arrays and methods of use thereof

A method of coating a microneedle array comprising: providing a microneedle array having a substrate and at least one needle; providing a removable masking layer on the microneedle array such that the substrate is at least partially covered by the masking layer and the at least one needle remains at least partially exposed; and applying a coating material to at least a portion of the exposed portion of the microneedle array.

Masking method for coating a microneedle array

The invention comprises a medicinal aerosol composition comprising a propellant, an excipient comprising a functionalized polyethyleneglycol, and a drug. The invention also comprises particulate medicinal compositions comprising particles with a mean mass aerodynamic diameter of less than about 10 microns that incorporate an excipient comprising a functionalized polyethyleneglycol.

Medicinal aerosol compositions with a functionalized polyethyleneglycol excipient

Methods, compounds, and medicinal formulations utilizing biocompatible polymers for delivery of a drug, particularly for solubilizing, stabilizing and/or providing sustained release of drug from topical, implantable, and inhalation systems. Many of the methods, compounds, and medicinal formulations are particularly suitable for oral and/or nasal inhalation and use polymers of the formula &#x2014;[X&#x2014;R&#x2014;C(O)]&#x2014; wherein each Ris an independently selected organic group that links the &#x2014;X&#x2014; group to the carbonyl group, and each X is independently oxygen, sulfur, or catenary nitrogen.

Biocompatible compounds for sustained release pharmaceutical drug delivery systems

The invention comprises a medicinal aerosol composition comprising a propellant, an excipient comprising an acid or amine end-group and at least one and no more than two amide and/or ester functional groups, and a drug. The invention also comprises particulate medicinal compositions comprising particles with a mean mass aerodynamic diameter of less than about 10 microns that incorporate an excipient containing an acid or amine end-group and at least one and no more than two amide and/or ester functional groups.

Medicinal aerosol compositions with an amide and/or ester containing excipient compound

A transdermal drug delivery device involving a macromonomer-containing acrylate or methacrylate copolymer, a softener, and a drug. Also a pressure sensitive skin adhesive involving a macromonomer containing acrylate or methacrylate copolymer and a softener.

Matrix for transdermal drug delivery

The present invention relates to a pressure sensitive adhesive composition comprising a copolymer comprising pyrrolidonoethyl acrylate or pyrrolidonoethyl methacrylate. This composition may be used as part of a transdermal drug delivery device.

Pyrrolidonoethyl (meth)acrylate containing pressure sensitive adhesive compositions

Articles, such as high density arrays, on heat-relaxable substrates that can be relaxed by exposure to thermal energy are disclosed, along with methods of manufacturing the arrays, and systems/apparatus for relaxing arrays using electromagnetic energy. The arrays may themselves include electromagnetic energy sensitive material in their construction, in which case exposure of the arrays to suitable electromagnetic energy can provide the thermal energy required to cause the arrays to relax. In other embodiments, the arrays may not include an electromagnetic energy sensitive material in their construction, in which case the arrays may be heated indirectly, i.e., by locating the arrays within a system or apparatus that includes an electromagnetic energy sensitive material and transferring the thermal energy from the electromagnetic energy sensitive material to the array by, e.g., conduction.

Heat-relaxable substrates and arrays

Methods, compounds, and medicinal formulations utilizing biocompatible polymers for delivery of a drug, particularly for solubilizing, stabilizing and/or providing sustained release of drug from topical, implantable, and inhalation systems. Many of the methods, compounds, and medicinal formulations are particularly suitable for oral and/or nasal inhalation and use polymers of the formula &mdash;&lsqb;X&mdash;R &mdash;C(O)&rsqb;&mdash; wherein each R is an independently selected organic group that links the &mdash;X&mdash; group to the carbonyl group, and each X is independently oxygen, sulfur, or catenary nitrogen.

Medicinal aerosol solution formulation with biocompatible polymer

Methods, compounds, and medicinal formulations utilizing biocompatible polymers for delivery of a drug, particularly for solubilizing, stabilizing and/or providing sustained release of drug from topical, implantable, and inhalation systems. Many of the methods, compounds, and medicinal formulations are particularly suitable for oral and/or nasal inhalation and use polymers of the formula --[X--R.sup.1 --C(O)]-- wherein each R.sup.1 is an independently selected organic group that links the --X-- group to the carbonyl group, and each X is independently oxygen, sulfur, or catenary nitrogen.

Biocompatible compounds for pharmaceutical drug delivery systems

A medicinal aerosol formulation containing a particulate drug and a diol/diacid condensate as a dispersing aid.

Aerosol formulation containing a diol-diacid derived dispersing aid

A medicinal aerosol formulation containing a particulate drug and a dispersing aid derived from a hydroxyacid, a mercapto acid, or an amino acid.

Aerosol formulation containing an ester-, amide-, or

The present invention provides a shaped permeable polymeric material including a hydrophobic portion and a hydrophilic portion, wherein the material is crosslinked. This material is prepared by a method including the steps preparing a crosslinkable composition having a hydrophobic portion and a hydrophilic portion; placing the crosslinkable composition in a mold; gelling the crosslinkable composition to form a shaped gelled polymeric composition comprising a hydrophobic portion, a hydrophilic portion, and a liquid portion; and exchanging the liquid portion with an exchange liquid to form the permeable polymeric material. Preferably this material is used in a blood gas sensor.

Growing community of inventors

Saint Paul, MN, United States of America

Daniel C Duan